Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics aimed at treating complement-mediated neurodegenerative and autoimmune diseases. The company's unique scientific approach targets C1q, the initiating molecule of the classical complement pathway, to halt the inflammatory cascade before it starts, providing significant potential benefits across a range of diseases affecting the body, brain, and eye.
Annexon’s primary product candidates include:
- ANX005: A monoclonal antibody designed to block C1q, currently in pivotal Phase 3 trials for Guillain-Barré Syndrome (GBS) and showing promising results in reducing muscle strength loss and nerve damage.
- ANX007: An antigen-binding fragment aimed at treating geographic atrophy (GA) in the eye, demonstrating notable protection against vision loss and retinal damage in Phase 2 trials.
- ANX1502: An oral small molecule inhibitor targeting autoimmune diseases, expected to generate proof-of-concept data in the second half of 2024.
In recent developments, Annexon announced positive top-line results from their Phase 3 trial of ANX005 in GBS, showing significant improvements in clinical outcomes and muscle strength. This trial marks a major milestone as ANX005 could become the first targeted treatment for GBS in the U.S. The company also showcased ANX007's potential in preserving retinal structures and vision in GA patients, with Phase 3 trials set to commence in 2024.
Financially, Annexon maintains a robust balance sheet with approximately $260 million in cash and equivalents, providing a runway into mid-2026. The company recently completed a public offering to raise additional capital, further strengthening its financial position to advance its clinical programs.
Annexon continues to advance its pipeline rigorously, with multiple upcoming milestones that have the potential to generate substantial value for patients and shareholders alike.
Annexon, a clinical-stage biopharmaceutical company, announced inducement grants to two new non-executive employees. These equity awards were made under the 2022 Employment Inducement Award Plan and approved on June 14, 2024, in line with Nasdaq Listing Rule 5635(c)(4). The new employees received options to purchase 109,300 shares of Annexon common stock. The exercise price is $5.62 per share, matching the closing stock price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting after the first year and the remaining shares vesting monthly thereafter.
Annexon announced the pricing of its public offering of 13,001,120 shares of common stock at $6.25 per share, potentially raising $125 million before underwriting discounts and commissions. Additionally, pre-funded warrants for 7,000,000 shares at $6.249 per share were also part of the offering. The proceeds aim to further the company's late-stage clinical platform targeting neuroinflammatory diseases. The offering is expected to close on June 7, 2024, subject to customary conditions. J.P. Morgan, Jefferies, TD Cowen, BofA Securities, and Wells Fargo Securities are joint book-running managers for the offering. More details are available through the SEC's website.
Annexon announced a proposed public offering of $125 million in common stock. The company may also grant underwriters an option to purchase an additional $18.75 million in shares. The offering's completion is uncertain and subject to market conditions. J.P. Morgan, Jefferies, TD Cowen, BofA Securities, and Wells Fargo Securities will act as joint book-running managers. Shares will be offered under a shelf registration statement filed with the SEC. The final terms will be disclosed in a forthcoming final prospectus supplement.
Annexon announced positive results from its Phase 3 trial of ANX005 in Guillain-Barré syndrome (GBS). The trial showed a significant 2.4-fold improvement in the GBS-disability scale at week 8 with a 30 mg/kg dose (p=0.0058). Secondary endpoints, including muscle strength and nerve damage, also improved. ANX005 was well-tolerated with mild side effects. A real-world evidence study and regulatory submissions are expected by 2025. The company plans to present detailed data at an upcoming conference.
Annexon Biosciences, a clinical-stage biopharmaceutical company focused on complement-based medicines, will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET. The event will discuss the results of their Phase 3 clinical trial for a treatment targeting Guillain-Barré Syndrome (GBS). Interested parties in the U.S. and Canada can dial 1-877-407-0784, while international participants can use 1-201-689-8560. The conference ID is 13747058, and a live webcast and replay will be available on Annexon's website.
Annexon, a clinical-stage biopharmaceutical company, announced inducement grants for two new non-executive employees under its 2022 Employment Inducement Award Plan. Approved on May 11, 2024, in line with Nasdaq Listing Rule 5635(c)(4), these equity awards include options to purchase 52,590 shares of Annexon’s common stock. These options have a ten-year term, an exercise price of $4.50 per share (the closing price on May 15, 2024), and vest over four years. Specifically, 25% of the shares vest on the first anniversary of the grant date, with an additional 1/48th vesting monthly thereafter, provided the employees continue their service through the vesting dates.
Annexon, Inc. reported its first quarter 2024 financial results, highlighting multiple value-creating catalysts in their portfolio. Key anticipated milestones include Phase 3 data for ANX005 in Guillain-Barré Syndrome, Phase 3 trial initiation for ANX007 in Geographic Atrophy, and proof-of-concept data for ANX1502 in Chronic Autoimmune Conditions. The company boasts a strong balance sheet with cash of $264.9 million as of March 31, 2024.
Annexon, a biopharmaceutical company, will present at the Bank of America Health Care Conference. President and CEO, Douglas Love, will discuss the company's late-stage clinical platform for neuroinflammatory diseases. The event will be live-streamed on May 14, 2024, at 8:40 a.m. PT.
Annexon presented new data at the ARVO 2024 Annual Meeting showcasing ANX007's significant protection against vision loss in patients with geographic atrophy. The drug demonstrated preservation of key retinal structures, reduction of photoreceptor and RPE loss, and promising preclinical results supporting its mechanism of action. Plans for Phase 3 trials in 2024 were announced, highlighting the drug's potential to deliver functional benefits to patients.
Annexon, Inc. (Nasdaq: ANNX) will present data at the ARVO 2024 Annual Meeting showcasing the neuroprotective effects of ANX007 and C1q inhibition in Geographic Atrophy. The Phase 2 ARCHER trial results will be discussed, highlighting the protection of visual acuity and anatomical structure with ANX007 treatment. New preclinical data on the role of C1q in photoreceptor synapse elimination and the protective effects of C1q blockade in GA will also be presented.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
What does Annexon, Inc. specialize in?
What are Annexon's main product candidates?
What recent achievements has Annexon announced?
What is the financial condition of Annexon?
When are the next key milestones expected for Annexon’s pipeline?
What is the scientific approach of Annexon?
What is the potential impact of ANX007 on GA patients?
How does ANX005 work in treating GBS?
What regulatory designations has ANX005 received?
Where can I find more information about Annexon?
